| Why carry out this study? |
| Thiazolidinediones (TZDs) decrease urinary albumin excretion and improve albuminuria values in patients with type 2 diabetes mellitus (T2DM). |
| Lobeglitazone, a novel TZD developed in Korea, has been used in patients with T2DM. |
| To date, no study has assessed the efficacy of lobeglitazone on albuminuria |
| What was learned from the study? |
| This is the first study to evaluate the efficacy of lobeglitazone on albuminuria for 24 weeks in patients with T2DM, in comparison to pioglitazone. |
| Lobeglitazone was shown to have a tendency to improve albuminuria in patients with T2DM and had comparable effects on albuminuria as pioglitazone which has demonstrated beneficial effects. |
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.